Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.
完整摘要 · 中文译文
P环和αC螺旋压缩(PACC)突变构成非小细胞肺癌(NSCLC)中表皮生长因子受体(EGFR)突变的一个结构上独特的亚组,治疗选择有限。Firmonertinib是一种每日一次口服、可穿透血脑屏障、突变选择性EGFR酪氨酸激酶抑制剂,具有独特的三氟乙氧基侧链。Firmonertinib在EGFR PACC突变细胞和异种移植瘤中具有高抗增殖效力。在1b期FURTHER研究(NCT05364073)中,转移性EGFR PACC突变NSCLC患者随机接受一线firmonertinib 160 mg(n = 25)或240 mg(n = 22)治疗,确认的客观缓解率(ORR)分别为43%和68%,中位缓解持续时间分别为未达到和14.6个月,中位无进展生存期分别为11.1和16.0个月;治疗相关不良事件导致剂量减少(19%和24%)和停药(3%和0%)。基线时有脑转移患者的颅内ORR为47%(8/17)。结果支持进一步研究一线firmonertinib用于EGFR PACC突变NSCLC患者。
完整摘要 · 英文原文
P-loop and αC-helix compressing (PACC) mutations comprise a structurally distinct subgroup of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) with limited treatment options. Firmonertinib is a once-daily oral, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor with a unique trifluoroethoxy side chain. Firmonertinib had high anti-proliferative efficacy in EGFR PACC-mutant cells and xenografts. In the phase 1b FURTHER study (NCT05364073), patients with metastatic EGFR PACC-mutant NSCLC randomized to receive first-line firmonertinib 160 mg (n = 25) or 240 mg (n = 22) had confirmed objective response rates (ORRs) of 43% and 68%, median duration of response not reached and 14.6 months, and median progression-free survival of 11.1 and 16.0 months, respectively; treatment-related adverse events led to dose reductions (19% and 24%) and discontinuation (3% and 0%). Intracranial ORR among patients with brain metastases at baseline was 47% (8/17). Results support further study of first-line firmonertinib in patients with EGFR PACC-mutant NSCLC.
摘要 待译
P-loop and αC-helix compressing (PACC) mutations comprise a structurally distinct subgroup of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) with limited treatment options. Firmonertinib is a once-daily oral, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor with a unique trifluoroethoxy side chain. Firmonertinib had high anti-proliferative efficacy in EGFR PACC-mutant cells and xenografts.…